Cargando…

Genomic Mapping of Splicing-Related Genes Identify Amplifications in LSM1, CLNS1A, and ILF2 in Luminal Breast Cancer

SIMPLE SUMMARY: The alternative splicing (AS) process is highly relevant, affecting most of the hallmarks of cancer, such as proliferation, angiogenesis, and metastasis. Our study evaluated alterations in 304 splicing-related genes and their prognosis value in breast cancer patients. Amplifications...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noblejas-López, María del Mar, López-Cade, Igor, Fuentes-Antrás, Jesús, Fernández-Hinojal, Gonzalo, Esteban-Sánchez, Ada, Manzano, Aránzazu, García-Sáenz, José Ángel, Pérez-Segura, Pedro, La Hoya, Miguel De, Pandiella, Atanasio, Győrffy, Balázs, García-Barberán, Vanesa, Ocaña, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391113/ https://www.ncbi.nlm.nih.gov/pubmed/34439272 http://dx.doi.org/10.3390/cancers13164118

Ejemplares similares

Mapping of Genomic Vulnerabilities in the Post-Translational Ubiquitination, SUMOylation and Neddylation Machinery in Breast Cancer
por: Fuentes-Antrás, Jesús, et al.
Publicado: (2021)

Genomic mapping of copy number variations influencing immune response in breast cancer
por: López-Cade, Igor, et al.
Publicado: (2022)

Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer
por: Saiz-Ladera, Cristina, et al.
Publicado: (2021)

A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors
por: Pérez-Pena, Javier, et al.
Publicado: (2019)

Adoptive Cell Therapy in Breast Cancer: A Current Perspective of Next-Generation Medicine
por: Fuentes-Antrás, Jesús, et al.
Publicado: (2020)

Genomic Correlates of DNA Damage in Breast Cancer Subtypes
por: Cabañas Morafraile, Esther, et al.
Publicado: (2021)

Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates
por: Alcaraz-Sanabria, Ana, et al.
Publicado: (2022)

Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene
por: Noblejas-López, María del Mar, et al.
Publicado: (2018)

Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis
por: Saleh, Ramy R., et al.
Publicado: (2019)

Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1
por: Cimas, Francisco J., et al.
Publicado: (2020)

Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors
por: Morcillo-Garcia, Sara, et al.
Publicado: (2019)

Transcriptomic Profiles of CD47 in Breast Tumors Predict Outcome and Are Associated with Immune Activation
por: Noblejas-López, María del Mar, et al.
Publicado: (2021)

MZ1 co-operates with trastuzumab in HER2 positive breast cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2021)

Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors
por: Pérez-Peña, Javier, et al.
Publicado: (2017)

Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors
por: Alcaraz-Sanabria, Ana, et al.
Publicado: (2020)

Personalized therapies in the cancer "omics" era
por: Ocaña, Alberto, et al.
Publicado: (2010)

Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies
por: Ocana, Alberto, et al.
Publicado: (2017)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
por: Ocaña, Alberto, et al.
Publicado: (2020)

ILF2 and ILF3 are autoantigens in canine systemic autoimmune disease
por: Bremer, Hanna D., et al.
Publicado: (2018)

Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors
por: Fuentes-Antrás, Jesús, et al.
Publicado: (2023)

Transcriptome evolution from breast epithelial cells to basal-like tumors
por: Santpere, Gabriel, et al.
Publicado: (2017)

Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2022)

Crystal Structures of Lsm3, Lsm4 and Lsm5/6/7 from Schizosaccharomyces pombe
por: Wu, Donghui, et al.
Publicado: (2012)

Analysis of Lsm1p and Lsm8p domains in the cellular localization of Lsm complexes in budding yeast
por: Reijns, Martin A M, et al.
Publicado: (2009)

Lsm2 and Lsm3 bridge the interaction of the Lsm1-7 complex with Pat1 for decapping activation
por: Wu, Donghui, et al.
Publicado: (2014)

Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling
por: Montero, Juan Carlos, et al.
Publicado: (2015)

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results
por: Ocaña, Alberto, et al.
Publicado: (2018)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2019)

Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple‐negative breast cancer
por: Corrales‐Sánchez, Verónica, et al.
Publicado: (2020)

Erratum: Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

BET inhibitors as novel therapeutic agents in breast cancer
por: Ocaña, Alberto, et al.
Publicado: (2017)

Breast Cancer Heterogeneity and Response to Novel Therapeutics
por: Baliu-Piqué, Mariona, et al.
Publicado: (2020)

Generation of Antibody-Drug Conjugate Resistant Models
por: Gandullo-Sánchez, Lucía, et al.
Publicado: (2021)

HER3 in cancer: from the bench to the bedside
por: Gandullo-Sánchez, Lucía, et al.
Publicado: (2022)

Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers
por: Juan, Alberto, et al.
Publicado: (2022)

Comprehensive Bioinformatics Analysis of the Biodiversity of Lsm Proteins in the Archaea Domain
por: Payá, Gloria, et al.
Publicado: (2023)

Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
por: Díaz-Gil, Laura, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ab8kt2n5rb5nvja72g9j6rqt25